Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete Pathologic response after Neoadjuvant chemotherapy

被引:82
作者
Goldstein, Neal S.
Decker, David
Severson, Dawn
Schell, Scoff
Vicini, Frank
Margolis, Jeffrey
Dekhne, Nayana S.
机构
[1] William Beaumont Hosp, Dept Anat Pathol, Royal Oak, MI 48073 USA
[2] William Beaumont Hosp, Dept Med Oncol, Royal Oak, MI 48072 USA
[3] William Beaumont Hosp, Dept Surg Oncol, Royal Oak, MI 48072 USA
[4] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48072 USA
关键词
molecular classification system; invasive breast cancer; complete pathologic response; neoadjuvant chemotherapy; receptor status;
D O I
10.1002/cncr.22981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The molecular classification system categorizes invasive breast carcinomas according to their key driving biomarkers. In the current study, the authors evaluated whether response to neoadjuvant chemotherapy was correlated with the molecular classification groups. METHODS. Using immunohistochemistry, the molecular classification group (luminal-A, luminal-B, HER-2-variant, HER-2-classic, and basal phenotype) was retrospectively determined in 68 breast cancer patients who received neoadjuvant treatment. RESULTS. A total of 28 carcinoma patients (41.2%) achieved a compete pathologic response (CPR), including 2 of 15 patients classified as having luminal-A (13.3%), 4 of 16 patients classified as having luminal-B (25.0%), 10 of 12 patients classified as having HER-2-classic (83.3%), none of the 4 patients classified as having HER-2-variant, and 12 of 21 patients classified as having basal phenotype (57.1%) neoplasms. The CPR rate among patients with the HER-2-classic and basal neoplasms was 67% (22 of 33 neoplasms), compared with 17.1% (6 of 35 neoplasms) in the non-HER-2-classic/basal combined group (P < .001). Eleven carcinomas were initially diagnosed as invasive lobular carcinomas (pleomorphic and classic), 4 of which were luminal-A, 4 of which were luminal-B, 2 of which were HER-2-classic, and 1 of which was basal. On review, only 3 of these 11 cases remained classified as classic lobular carcinoma,;01 of which were classified as luminal-A, and none of these patients achieved a CPR. Four of the other 8 patients achieved a CPR. CONCLUSIONS. The molecular classification system is useful for identifying carcinoma patients who are most likely and those who are least likely to achieve a CPR. In the current study, all the morphologically classic lobular carcinomas were classified as luminal-A neoplasms, which may explain the low rate of CPR reported.
引用
收藏
页码:1687 / 1696
页数:10
相关论文
共 62 条
  • [1] Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
    Abd El-Rehim, DM
    Pinder, SE
    Paish, CE
    Bell, JA
    Rampaul, RS
    Blamey, RW
    Robertson, JFR
    Nicholson, RI
    Ellis, IO
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1532 - 1542
  • [2] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
    Abd El-Rehim, DM
    Ball, G
    Pinder, SE
    Rakha, E
    Paish, C
    Robertson, JFR
    Macmillan, D
    Blamey, RW
    Ellis, IO
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) : 340 - 350
  • [3] Allred DC, 1998, MODERN PATHOL, V11, P155
  • [4] High prognostic significance of residual disease after neoadjuvant chemotherapy:: a retrospective study in 710 patients with operable breast cancer
    Amat, S
    Abrial, C
    Penault-Llorca, F
    Delva, R
    Bougnoux, P
    Leduc, B
    Mouret-Reynier, MA
    Mery-Mignard, D
    Bleuse, JP
    Dauplat, J
    Curé, H
    Chollet, P
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 (03) : 255 - 263
  • [5] Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods
    Ambrogi, F
    Biganzoli, E
    Querzoli, P
    Ferretti, S
    Boracchi, P
    Alberti, S
    Marubini, E
    Nenci, I
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (03) : 781 - 790
  • [6] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27
    Bear, HD
    Anderson, S
    Brown, A
    Smith, R
    Mamounas, EP
    Fisher, B
    Margolese, R
    Theoret, H
    Soran, A
    Wickerham, DL
    Wolmark, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) : 4165 - 4174
  • [7] Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer
    Bergamaschi, Anna
    Kim, Young H.
    Wang, Pei
    Sorlie, Therese
    Hernandez-Boussard, Tina
    Lonning, Per E.
    Tibshirani, Robert
    Borresen-Dale, Anne-Lise
    Pollack, Jonathan R.
    [J]. GENES CHROMOSOMES & CANCER, 2006, 45 (11) : 1033 - 1040
  • [8] Billgren AM, 1999, ACTA ONCOL, V38, P597
  • [9] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Buzdar, AU
    Ibrahim, NK
    Francis, D
    Booser, DJ
    Thomas, ES
    Theriault, RL
    Pusztai, L
    Green, MC
    Arun, BK
    Giordano, SH
    Cristofanilli, M
    Frye, DK
    Smith, TL
    Hunt, KK
    Singletary, SE
    Sahin, AA
    Ewer, MS
    Buchholz, TA
    Berry, D
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3676 - 3685
  • [10] Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
    Chang, HY
    Nuyten, DSA
    Sneddon, JB
    Hastie, T
    Tibshirani, R
    Sorlie, T
    Dai, HY
    He, YDD
    van't Veer, LJ
    Bartelink, H
    van de Rijn, M
    Brown, PO
    van de Vijver, MJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) : 3738 - 3743